High Throughput Screening Market Worth USD 21,911.2 Million By 2022

PUNE, India - Oct. 3, 2017 - PRLog -- The global high throughput screening market is primarily driven by the increasing adoption of innovative approaches in pharmaceutical and biotechnology companies, rising investment by private equity firms and venture capitalists, increasing government funding for various R&D activities, growing healthcare spending, and various technological advancements in this field. Further, growing research in toxicology and stem cell research provide significant opportunities in this market. However, high cost for HTS, intricacy in the field of assay development, and government regulations for drug development obstructs the growth of this market to some extent.

The global high throughput screening market is mainly segmented by product & service (Consumables & Reagents, Instruments, Software & Services), by technology (Cell-based Assay, Ultra High Throughput Screening, Label-Free Technology, Lab On A Chip), by application (Stem Cell Research, Toxicology Assessment, Primary Screening, Target Identification), by end user (Pharmaceuticals and Biotechnology Industry, Academics and Research Institutes, Contract Research Organizations, and others), and by geography (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa).

Browse in-depth Report at http://www.meticulousresearch.com/product/high-throughput...

Based on products, the consumables & reagents segment dominated the overall market in 2016 and is also estimated to continue its dominance over the forecast period, owing to the availability of a wide variety of reagents, rising demand for consumables & reagents with increasing adoption of HTS in drug discovery, and continuous launch of innovative technology-based products in the global market.

Based on technology, cell-based assay segment commanded the largest share in 2016, owing to the large adoption of cell-based platforms to gain accurate and more relevant in vivo biological information in high-throughput drug screenings for target validation and ADMET (absorption, distribution, metabolism, elimination, and toxicity) in drug discovery.

On the basis of application, target identification segment held the largest share of the global high throughput screening market in 2016, owing to the rising adoption of high-throughput products for efficient, faster, and cost-effective identification of targets in early-stage drug discovery.

Based on the end user, the pharmaceuticals & biotechnology industry dominated the high throughput screening market in 2016, owing to higher adoption of high throughput screening assay for drug discovery and development and regenerative medicine in this industry.

Geographically, North America accounted for the major share of the global high throughput screening market in 2016, followed by Europe and Asia-Pacific region. The major share of the North American region is mainly attributed to the higher spending on pharmaceutical R&D, higher adoption of advanced HTS technologies in drug discovery & development, well-established healthcare system, availability of government funding, and the presence of leading players in this region. However, Asia-Pacific region is slated to register the fastest growth during the forecast period, primarily due to rising R&D expenditure, increasing pharmaceutical research outsourcing in the region owing to lower cost advantages, increasing government funding, and improving healthcare infrastructure. In addition, significantly growing pharmaceutical industry in Asia, primarily due to huge demand for medical care from large population base with increasing incidence & prevalence of chronic disease and aging population are expected to support the growth of HTS market in the region.

The leading companies have employed various strategies to expand their product and application offerings, global footprint, and augment their market shares. The key strategies followed by most companies in the global high throughput screening market were new product launches, mergers & acquisitions, and expansions. The key players in the global high throughput screening market are MERCK KGaA, Charles River Laboratories International, Inc., AXXAM S.p.A., Thermo Fisher Scientific Inc., Danaher Corporation, PerkinElmer Inc., Agilent Technologies Inc., Bio-Rad Laboratories, Inc., Tecan Trading AG, Aurora Biomed, Inc., and Hamilton Company.

Key questions answered in the report-

Which are the high growth market segments in terms of product, technology, application, end user, and regions/countries?

What is the historical market for high throughput screening across the globe?

What are the market forecasts and estimates from the period 2015-2022?

What are the major drivers, restrains, opportunities, and trends in the global high throughput screening market?

Who are the major players in the global high throughput screening market and what share of the market do they hold?

Who are the major players in various countries and what share of the market do they hold?

What are the competitive landscapes and who are the market leaders by sub-region in the global high throughput screening market?

What are the recent developments in the global high throughput screening market?

What are the different strategies adopted by the major players in the global high throughput screening market?

What are the geographical trends and high growth regions/ countries?

Who are the local emerging players in the global high throughput screening market and how do they compete with the global players?


About Meticulous Research™

Meticulous Research™ is one of the leading independent full service global market research and consulting companies focusing on medical devices, biotechnology, healthcare IT, pharmaceuticals, food and beverages, and agriculture domains. Meticulous Research produces global reports and custom studies for North America, Europe, Latin America, Asia-Pacific, and Middle East and Africa regions.

Email: sales@meticulousresearch.com

T: +91 744-7780008